National Healthcare Budget Impact Analysis of the Treatment for Osteoporosis and Fractures in Korea.
10.11005/jbm.2013.20.1.17
- Author:
Hwabok YI
1
;
Yong Chan HA
;
Young Kyun LEE
;
Young Taik LIM
Author Information
1. Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Economics;
Fractures bone;
Health expenditures;
Osteoporosis;
Republic of Korea
- MeSH:
Budgets;
Delivery of Health Care;
Health Care Costs;
Health Expenditures;
Humans;
Income;
Insurance;
Insurance Coverage;
Korea;
National Health Programs;
Osteoporosis;
Osteoporotic Fractures;
Republic of Korea
- From:Journal of Bone Metabolism
2013;20(1):17-23
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This study was to determine the impact on the national healthcare expenditure for the treatment of osteoporosis and fractures if the coverage period for osteoporosis medication was extended from maximum a year to continuous period as required. METHODS: Preserving the current reimbursement guidelines, maximum one year's coverage for osteoporosis medication was set as scenario A. Continuous coverage for patients who require medication was set as scenario B. As costs of medical service utilization are paid by the Korean National Health Insurance Program, all items were investigated and analyzed from the payer's perspective. The combined treatment costs for osteoporosis and osteoporotic fractures were assessed for each scenario. RESULTS: Over five years the cost of osteoporosis medication in scenario A will increase from 184.3 billion KRW to 204.6 billion KRW. The cost of osteoporotic fracture treatment will increase from 1,037.3 billion KRW to 1,822.7 billion KRW. In scenario B, the cost of osteoporosis medication will increase from 209.5 billion KRW to 388.1 KRW. The cost of osteoporotic fracture treatment will increase from 600.0 billion KRW to 1,054.3 billion KRW. The result showed savings of 2.50 trillion KRW cumulatively for five years when reimbursement coverage for osteoporosis treatments is extended from one year to as long as it's clinically required. CONCLUSIONS: This study demonstrates that effective osteoporosis management through appropriate insurance coverage for osteoporosis medication should be considered not only for the patient's viewpoint, but in terms of national insurance budget as well.
